Rafael Holdings Inc Dossier - Source-backed chat

Rafael Holdings Inc

RFLNYSE

SectorReal Estate

IndustryReal Estate Services

Beta (adjusted)0.58

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.50Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $78M

Enterprise Value $48.1M

Shares Outstanding 55.6M diluted

Next Earnings Date28 Oct 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Rafael Holdings, Inc. (NYSE: RFL) is at a critical regulatory and clinical juncture following its strategic consolidation of Cyclo Therapeutics. The company's investment thesis is almost entirely binary, centered on its lead candidate, Trappsol® Cyclo™, which recently completed the 'last patient, last visit' milestone in its pivotal Phase 3 TransportNPC™ trial for Niemann-Pick Disease Type C1 (NPC1). While the path to a New Drug Application (NDA) submission in H2 calendar 2026 is clear, the company faces a highly competitive landscape with recently approved therapies (Zevra's Miplyffa and IntraBio's Aqneursa) and a declining cash runway ($30.5M as of April 30, 2026) relative to its elevated R&D burn rate. A Hold recommendation is warranted until topline Phase 3 data is unblinded in H2 2026.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.50

The Phase 3 trial fails to meet its primary efficacy endpoints or reveals safety concerns, leading to a Complete Response Letter (CRL) or program termination. With its primary asset invalidated and cash reserves depleted by high clinical trial costs, the company is forced to restructure or liquidate, resulting in severe capital loss for equity holders.

Base CaseCentral scenario

$2.50

The Phase 3 TransportNPC™ trial yields positive topline results in H2 calendar 2026, demonstrating comparable or superior efficacy to existing treatments. Rafael successfully submits its NDA to the FDA by late 2026. The company secures a commercial partner or non-dilutive financing to extend its cash runway through the regulatory review period, mitigating immediate dilution risk.

Bull CaseUpside scenario

$5.00

The Phase 3 TransportNPC™ trial yields highly positive topline results in H2 calendar 2026, demonstrating superior efficacy and safety. The FDA grants priority review, leading to approval in early 2027. Rafael secures a lucrative global commercial partnership with a major pharmaceutical firm, providing substantial non-dilutive upfront cash and milestone payments, driving the stock price toward its bull-case target.

Scenarios reflect our research view at the research date.

Key Investment Merits

Completed the 'last patient, last visit' milestone in the largest-ever controlled clinical trial for NPC1 (94 patients across 13 countries).
Clear regulatory path with a pre-NDA meeting already completed with the FDA and an expected NDA submission in H2 calendar 2026.
Orphan Drug Designation in both the US and EU provides potential market exclusivity and eligibility for a valuable Priority Review Voucher.

Key Investment Risks

High binary clinical risk; the investment thesis depends almost entirely on the unblinding of Phase 3 topline data in H2 calendar 2026.
Limited cash runway ($30.5M as of April 30, 2026) against a high R&D burn rate driven by the consolidation of Cyclo Therapeutics' expenses.
Intense commercial competition from recently approved NPC treatments, including Zevra Therapeutics' Miplyffa and IntraBio's Aqneursa.

Thesis Invalidation Triggers

Failure of the Phase 3 TransportNPC™ trial to meet its primary clinical endpoints.
A delay or refusal by the FDA to accept the NDA submission in H2 calendar 2026.
Severe equity dilution through highly unfavorable capital raising terms prior to data unblinding.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.